Abstract
The effect of Vitamin E on the incidence and severity of RLF and BPD remains unclear. A prospective randomized controlled trial to further assess the role of Vit E in infants of 750-1500 gm to date includes 79 surviving infants (total n=105) of 29.5 wk (26-33 wk) gest., and birth weight 1130 gm (760-1500 gm). Randomization into groups was performed according to birth weight, (250 gm increments) initial Fi02 and need for intubation. Parenteral Vit E was administered on a fixed schedule within 12 hr of birth to 30 of the infants for 4 wk for a total dosage of 430 units followed by oral administration if tolerating feeds, or continued parenteral administration until 6 wk of age. There was no clinically significant difference between the two groups. Vit E levels were not significantly different at birth but were significantly higher in the Vit E group through-out the first 6 wk (33.8 vs. 6.9 mg/l, p<.001).
Three infants in the control group and 1 in the Vit E group required cryopexy prior to discharge. Parenteral Vit E decreases the severity without effecting the incidence of RLF and appears to have no effect on the incidence or severity of BPD.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Finer, N., Peters, K., Schindler, R. et al. 1301 VITAMIN E. RETROLENTAL FIBROPLASIA (RLF) AND BRONCHOPULMONARY DYSPLASIA (BPD): CONTROLLED TRIAL IN THE LOW BIRTH WEIGHT NEONATE. Pediatr Res 15 (Suppl 4), 660 (1981). https://doi.org/10.1203/00006450-198104001-01330
Issue Date:
DOI: https://doi.org/10.1203/00006450-198104001-01330